MICHAEL JAMES OVERMAN to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Antimetabolites, Antineoplastic.
Connection Strength
0.315
-
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
Score: 0.201
-
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
Score: 0.069
-
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
Score: 0.027
-
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
Score: 0.017